An interventional study of Antihypertensive treatment in Preeclampsia, Gestational Hypertension and Hypertensive Disorder of Pregnancy, sponsored by University of Alabama at Birmingham. Recruiting at 2 sites in United States. Open to female participants aged 14 Years to 49 Years. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment
Among 228 studies in Pre-Eclampsia with a site in United States — 60 open to participants now, 76 under way, 6 of them phase 3. Pre-Eclampsia · United States.
Among the 228 studies in Pre-Eclampsia with a site in United States, this one is the 54th largest by planned enrollment of the 159 interventional ones, is one of 17 that started in 2023, is one of 71 with no phase, reaches primary completion later than 22 of the 75 other live ones, and was the 158th registered.
916 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
This study's planned enrollment of 132 is above the median of 110 across 480 interventional studies indexed under Pre-Eclampsia.
Browse Pre-Eclampsia studies →60 of the 228 studies in Pre-Eclampsia with a site in United States are open now, in 2 countries. Each count lists the studies.
Of the 162 Pre-Eclampsia studies recruiting now, 81 (50%) set no upper age limit and 80 (49%) stop at 75 or younger; 18 take children under 18; 60 take healthy volunteers.
This study: 14 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →228 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 17 started in 2023.
Median enrollment 89 across the 159 interventional studies, 125 across the 69 observational. Of the 126 that completed or were terminated, 54 (43%) have results posted.
13 of 228 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,421 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 5 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
27 of the studies in Pre-Eclampsia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222852Phase 3Women and Infants Hospital of Rhode IslandCardiovascular Protection After Preeclampsia With Enalapril | 2027-10-15 |
| NCT05709483Rockefeller UniversityPredictors of Aspirin Failure in Preeclampsia Prevention | 2026-11-01 |
| NCT07293728Oregon Health and Science UniversityA Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia | 2026-12 |
| NCT07356518Wake Forest University Health SciencesTelehealth and Remote Blood Pressure | 2026-12 |
| NCT05676476University of Alabama at BirminghamThe ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy. | 2026-12 |
Among the 228 studies in Pre-Eclampsia with a site in United States, from their registry updates:
The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.
Hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia, are characterized by new onset high blood pressure in pregnancy and constitute a major cause of maternal and perinatal morbidity and mortality; severe hypertension (blood pressure ≥160/110 mmHg) is a common trigger for antihypertensive treatment and preterm delivery. We propose a clinical trial that will test whether lowering the blood pressure in women with hypertensive disorders of pregnancy at \<36 weeks' gestation to \<140/90 mmHg will prolong pregnancy and, therefore, improve maternal and fetal/neonatal outcomes. Data generated in this study, along with knowledge and skills acquired by the candidate in the complementary career development plan, will facilitate an independent research career focused on hypertension and cardiovascular disease in pregnancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Antihypertensive treatment for a BP goal of less than 140/90 mmHg
Drug: Antihypertensive treatment
Antihypertensive treatment only if BP ≥ 160/110 mmHg
Antihypertensive treatment to goal of less than 140/90 mmHg
Mean number of days from randomization to delivery
Duration of prolongation of pregnancy
Time frame: From randomization to delivery, up to 14 weeks
Perinatal morbidity
Composite of NICU admission ≥2 days, bronchopulmonary dysplasia, necrotizing enterocolitis, intraventricular hemorrhage, retinopathy of prematurity, or fetal or newborn death within 6 weeks after birth; individual elements of the composite, the frequency of small for gestational age neonates, birthweight.
Time frame: 6 weeks
Neonatal healthcare utilization
NICU and hospital length of stay
Time frame: 6 weeks
Maternal morbidity
Composite of severe hypertension, pulmonary edema, heart failure, eclampsia, stroke, liver dysfunction, acute renal failure, thrombocytopenia, abruption, ICU admission, postpartum hospital readmission for hypertension management, or death within 6 weeks of delivery; individual elements of the composite.
Time frame: From randomization to 6 weeks after delivery, up to 20 weeks
Maternal healthcare utilization
Antepartum and postpartum hospital length of stay, ICU admission, postpartum readmission.
Time frame: From randomization to 6 weeks after delivery, up to 20 weeks
Plan to share: No
Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.
Of 171 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 46 months is above that.
Counting every sponsor, half of 176 studies reached it within 24 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →